How have the 6 stocks performed since I featured them on 25 Dec 2022?

AHEALTH:

Share price rose from RM2.27 to RM2.46.(+8.37%) Not bad.
My favourite stock has performed the way I'd expected, steady growth + consistent dividends. 
Jun 2023 QR was abnormally high, because they sold off Straits Apex.
Probably one of the safest stocks to invest on Bursa. 

HARTA:

Share price surged from RM1.69 to RM2.69(+59.17%). Excellent returns. 

It is always darkest before dawn.  

While gloves competition has intensified, HARTA should have a better 2-3 years ahead.
It is hoped that its technology will keep itself ahead from competitors. 

IOICORP:

Share price inched up from RM3.80 to RM4.06(+6.84%). Not bad.

The plantation sector faced headwinds of lower CPO prices than last year, & IOICORP was no exception. 

Lower CPO prices & lower oleochemical & refining margins dragged performance down. 

Nevertheless, IOICORP remains a reliable company with the founder's family still at helm.

CDB (CELCOM-DIGI):

Share price climbed from RM3.73 to RM4.09(+9.65%).

The merger of Celcom-Digi still needs more time for synergies between them to happen.

CDB's business is still a resilient one, albeit lacking growth. 

HEIM:

Share price dipped from RM24.04 to RM23.14(-3.74%).

High raw material costs and a reduction from last year's high base effect dampened this year's profits.
However, good thing that ROE still is at admirably high levels & the alcohol excise duties were not increased. 

*Note: PESTECH had been removed due to material uncertainties, rendering it, in my view, unfit for investment purposes.

CONCLUSION:

Most stocks above generated positive return, in line with the more bullish market in 2023 compared to 2022. 

While the returns are unexciting, the above companies have stood the test of time. Investors need not worry too much about the next quarter earnings crash. These companies' dividends are also comparable to FD rates (with exception of HARTA since they're conserving cash now)

Disclaimer: This article is not tailored financial advice, but mere general stock sharing / observations. Please do further due diligence. The author owns all abovementioned shares.